Peripheral Nerve Amyloidosis

  • Adam J. LoavenbruckEmail author
  • JaNean K. Engelstad
  • Christopher J. Klein
Part of the Current Clinical Pathology book series (CCPATH)


In this chapter, we provide an overview of peripheral nerve amyloidosis, focusing on both universal and subtype-specific pathologic features. In the great majority of cases of amyloidosis involving peripheral nerve, amyloid fibrils are either formed by immunoglobulin light chains stemming from systemic plasma cell dyscrasia (primary or AL amyloidosis) or else mutant transthyretin (TTR). Peripheral neural involvement is a common feature and hallmark of amyloidosis—reported to occur in 17–35 % of AL amyloidosis cases, and in a majority of cases of TTR amyloidosis. Other than AL and TTR amyloidosis, only rare kindreds with a short list of amyloidogenic mutations, such as gelsolin and apolipoprotein A1, are known to develop amyloid neuropathy. Pathologic features are outlined in detail in the context of these amyloid subtypes, and clinical details and issues are reported briefly.


Amyloidosis Peripheral neuropathy Amyloid neuropathy Peripheral nerve amyloidosis Autonomic neuropathy Nerve pathology Nerve biopsy 


  1. 1.
    Kyle A, Kelly JJ, Dyck PJ. Amyloidosis and neuropathy. In: Dyck P, editor. Peripheral neuropathies. Philadelphia, PA: Saunders; 2005. p. 2427–51.CrossRefGoogle Scholar
  2. 2.
    Adams D. Hereditary and acquired amyloid neuropathies. J Neurol. 2001;248(8):647–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Klein CJ, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–9.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    De Navasquez S, Treble HA. A case of primary generalized amyloid disease with involvement of the nerves. Brain. 1938;61:12.CrossRefGoogle Scholar
  6. 6.
    De Bruyn RS, Stern RO. A case of the progressive hypertrophic polyneuritis of Dejerine and Sottas, with pathological examination. Brain. 1929;52(1):23.CrossRefGoogle Scholar
  7. 7.
    Krucke W. Histopathologie der Polyneuritis und Polyneuropathie. Dtsch Z Nervenheilkd. 1959;180:1–39.CrossRefGoogle Scholar
  8. 8.
    Krucke W. Zur pathologischen Anatomie der Paramyloidose. Acta Neuropathol (Berl). 1963;Suppl. II:74–93.Google Scholar
  9. 9.
    Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Horta JS, Trincao R. Anatomie pathologique de la paramyloidose de “type Portugais”. Acta Neuropathol (Berl). 1963;Suppl. II:54–65.Google Scholar
  11. 11.
    Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol. 1969;20(5):490–507.CrossRefPubMedGoogle Scholar
  12. 12.
    Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959;183(4669):1202–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Cohen AS, Shirahama T, Skinner M. Electron microscopy of amyloid. In: Harris I, editor. Electron microscopy of protein. London: Academic; 1982. p. 165–205.Google Scholar
  14. 14.
    Rajani B, Rajani V, Prayson RA. Peripheral nerve amyloidosis in sural nerve biopsies: a clinicopathologic analysis of 13 cases. Arch Pathol Lab Med. 2000;124(1):114–8.PubMedGoogle Scholar
  15. 15.
    Kelly JJ. Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis. 2006;3(4):173–81.PubMedGoogle Scholar
  16. 16.
    Consales A, et al. Amyloidoma of the brachial plexus. Surg Neurol. 2003;59(5):418–23. Discussion 423.CrossRefPubMedGoogle Scholar
  17. 17.
    Gabet JY, et al. [Amyloid pseudotumor of the sciatic nerve]. Rev Neurol. 1989;145(12):872–6.PubMedGoogle Scholar
  18. 18.
    Haridas A, et al. Primary isolated amyloidoma of the lumbar spine causing neurological compromise: case report and literature review. Neurosurgery. 2005;57(1):E196. Discussion E196.CrossRefPubMedGoogle Scholar
  19. 19.
    Ladha SS, et al. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst. 2006;11(4):346–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Laeng RH, et al. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production. Cancer. 1998;82(2):362–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Pizov G, Soffer D. Amyloid tumor (amyloidoma) of a peripheral nerve. Arch Pathol Lab Med. 1986;110(10):969–70.PubMedGoogle Scholar
  22. 22.
    Porchet F, Sonntag VK, Vrodos N. Cervical amyloidoma of C2. Case report and review of the literature. Spine. 1998;23(1):133–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Unal F, et al. Skull base amyloidoma. Case report. J Neurosurg. 1992;76(2):303–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang AK, et al. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008;83(11):1226–30.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Meretoja J. Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet. 1973;4(3):173–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Luttmann RJ, et al. Hereditary amyloidosis of the Finnish type in a German family: clinical and electrophysiological presentation. Muscle Nerve. 2010;41(5):679–84.PubMedGoogle Scholar
  27. 27.
    Tracy JK, Klein CJ. Corneal lattice dystrophy, facial weakness and sensorimotor polyneuropathy-gelsolin amyloidosis. In: Dyck PJ, Amrani K, Klein CJ, Dyck PJB, Low PA, Engelstad J, Spinner RJ editors.Companion to peripheral neuropathy: illustrated cases and new developments. Philadelphia, PA: Saunders; 2011, p. 155–8.Google Scholar
  28. 28.
    Brett M, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain. 1999;122(Pt 2):183–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Klein CJ, et al. Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Neurology. 1998;51(5):1462–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Andrews TR, et al. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002;77(12):1287–90.CrossRefPubMedGoogle Scholar
  31. 31.
    Kernohan JW, Woltman HW. Amyloid neuritis. Arch Neurol Psychiatr. 1942;47:132–40.CrossRefGoogle Scholar
  32. 32.
    Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 1994;91(25):12243–7.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Simmons LK, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994;45(3):373–9.PubMedGoogle Scholar
  34. 34.
    Garces-Sanchez M, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37(4):490–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13(6):1235–48.CrossRefPubMedGoogle Scholar
  36. 36.
    Krebs MR, et al. The formation of spherulites by amyloid fibrils of bovine insulin. Proc Natl Acad Sci U S A. 2004;101(40):14420–4.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Unal A, Sutlap PN, Kyyyk M. Primary solitary amyloidoma of thoracic spine: a case report and review of the literature. Clin Neurol Neurosurg. 2003;105(3):167–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54(4):271–99.CrossRefGoogle Scholar
  39. 39.
    Krishnan J, et al. Tumoral presentation of amyloidosis (amyloidomas) in soft tissues. A report of 14 cases. Am J Clin Pathol. 1993;100(2):135–44.PubMedGoogle Scholar
  40. 40.
    Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med. 2008;132(1):14. Author reply 14–5.PubMedGoogle Scholar
  41. 41.
    Lachmann HJ, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91.CrossRefPubMedGoogle Scholar
  42. 42.
    Vrana JA, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Solomon A, Kyle A, Frangione B. Light chain variable region subgroups of monoclonal immunoglobulins in amyloidosis-AL. In: Glenner GG, Osserman EF, Benditt EP, editors. Amyloidosis. New York: Plenum; 1986.Google Scholar
  44. 44.
    Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(2):180–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Gertz MA, Kyle RA. Primary systemic amyloidosis—a diagnostic primer. Mayo Clin Proc. 1989;64(12):1505–19.CrossRefPubMedGoogle Scholar
  46. 46.
    Kyle RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol. 2010;85(10):787–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol. 1990;10(1):49–87.CrossRefPubMedGoogle Scholar
  50. 50.
    Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol. 2004;16(1):67–75.CrossRefPubMedGoogle Scholar
  51. 51.
    Duston MA, et al. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med. 1989;149(2):358–60.CrossRefPubMedGoogle Scholar
  52. 52.
    Kyle RA, Greipp PR, O’Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68(1):220–4.PubMedGoogle Scholar
  53. 53.
    Vallat JM, et al. Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy. Muscle Nerve. 2008;38(1):904–11.CrossRefPubMedGoogle Scholar
  54. 54.
    Moorhouse DF, Fox RI, Powell HC. Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy. Acta Neuropathol. 1992;84(5):484–94.CrossRefPubMedGoogle Scholar
  55. 55.
    Lamarca J, Casquero P, Pou A. Mononeuritis multiplex in Waldenstrom’s macroglobulinemia. Ann Neurol. 1987;22(2):268–72.CrossRefPubMedGoogle Scholar
  56. 56.
    Figueroa JJ, et al. Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. J Peripher Nerv Syst. 2012;17(2):182–90.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Valleix S, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med. 2012;366(24):2276–83.CrossRefPubMedGoogle Scholar
  58. 58.
    Kang GH, et al. A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy. Korean Circ J. 2011;41(4):209–12.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Pitkanen P, Westermark P, Cornwell 3rd GG. Senile systemic amyloidosis. Am J Pathol. 1984;117(3):391–9.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Kyle RA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101(4):395–400.CrossRefPubMedGoogle Scholar
  61. 61.
    Sueyoshi T, et al. Spinal multifocal amyloidosis derived from wild-type transthyretin. Amyloid. 2011;18(3):165–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Stangou AJ, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66(2):229–33.CrossRefPubMedGoogle Scholar
  63. 63.
    Olofsson BO, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002;73(5):745–51.CrossRefPubMedGoogle Scholar
  64. 64.
    Dubrey SW, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64(1):74–80.CrossRefPubMedGoogle Scholar
  65. 65.
    Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–7.PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Thomas PK. Genetic factors in amyloidosis. J Med Genet. 1975;12(4):317–26.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Varga J, Wohlgethan JR. The clinical and biochemical spectrum of hereditary amyloidosis. Semin Arthritis Rheum. 1988;18(1):14–28.CrossRefPubMedGoogle Scholar
  68. 68.
    Ikeda K, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2008;70(17):1576. Author reply 1576–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Plante-Bordeneuve V, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Cappellari M, et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst. 2011;16(2):119–29.CrossRefPubMedGoogle Scholar
  71. 71.
    Misu K, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951–62.CrossRefPubMedGoogle Scholar
  72. 72.
    Meretoja J, Teppo L. Histopathological findings of familial amyloidosis with cranial neuropathy as principal manifestation. Report on three cases. Acta Pathol Microbiol Scand A. 1971;79(5):432–40.PubMedGoogle Scholar
  73. 73.
    Chen CD, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J. 2001;20(22):6277–87.PubMedCentralCrossRefPubMedGoogle Scholar
  74. 74.
    Kiuru-Enari S, et al. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol. 2002;61(6):565–71.PubMedGoogle Scholar
  75. 75.
    Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid. 1998;5(1):55–66.CrossRefPubMedGoogle Scholar
  76. 76.
    de Sousa MM, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol. 2000;156(6):1911–7.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Joy T, et al. APOA1 related amyloidosis: a case report and literature review. Clin Biochem. 2003;36(8):641–5.CrossRefPubMedGoogle Scholar
  78. 78.
    Nichols WC, et al. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990;8(2):318–23.CrossRefPubMedGoogle Scholar
  79. 79.
    Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology. 1969;19(1):10–25.CrossRefPubMedGoogle Scholar
  80. 80.
    Booth DR, et al. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM. 1995;88(10):695–702.PubMedGoogle Scholar
  81. 81.
    Soutar AK, et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A. 1992;89(16):7389–93.PubMedCentralCrossRefPubMedGoogle Scholar
  82. 82.
    Persey MR, et al. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int. 1998;53(2):276–81.CrossRefPubMedGoogle Scholar
  83. 83.
    Hamidi Asl K, et al. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun. 1999;257(2):584–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Kumar SK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12–8.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Dispenzieri A, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10):3960–3.CrossRefPubMedGoogle Scholar
  86. 86.
    Takei Y, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med. 2005;44(11):1151–6.CrossRefPubMedGoogle Scholar
  87. 87.
    Yamamoto S, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–604.CrossRefPubMedGoogle Scholar
  88. 88.
    Jono H, et al. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochem J. 2011;437(1):35–42.CrossRefPubMedGoogle Scholar
  89. 89.
    Adams D, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.CrossRefPubMedGoogle Scholar
  90. 90.
    Tojo K, et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006;56(4):441–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–49.CrossRefPubMedGoogle Scholar
  92. 92.
    Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67.PubMedCentralCrossRefPubMedGoogle Scholar
  93. 93.
    Bulawa CE, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  94. 94.
    Coelho T, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.PubMedCentralCrossRefPubMedGoogle Scholar
  95. 95.
    Benson MD, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33(5):609–18.CrossRefPubMedGoogle Scholar
  96. 96.
    Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov. 2002;1(4):267–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Adam J. Loavenbruck
    • 1
    Email author
  • JaNean K. Engelstad
    • 2
  • Christopher J. Klein
    • 2
  1. 1.Kennedy Laboratory, Department of NeurologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Peripheral Nerve LaboratoryMayo ClinicRochesterUSA

Personalised recommendations